ES2149979T3 - Composicion estabilizada para la administracion oral de peptidos. - Google Patents

Composicion estabilizada para la administracion oral de peptidos.

Info

Publication number
ES2149979T3
ES2149979T3 ES95914605T ES95914605T ES2149979T3 ES 2149979 T3 ES2149979 T3 ES 2149979T3 ES 95914605 T ES95914605 T ES 95914605T ES 95914605 T ES95914605 T ES 95914605T ES 2149979 T3 ES2149979 T3 ES 2149979T3
Authority
ES
Spain
Prior art keywords
oral administration
peptides
covered
stabilized composition
spheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95914605T
Other languages
English (en)
Inventor
Anne Fjellestad-Paulsen
Christina Ahlm-Soderberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Application granted granted Critical
Publication of ES2149979T3 publication Critical patent/ES2149979T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPUESTO FARMACEUTICO SOLIDO PARA LA ADMINISTRACION ORAL DE PEPTIDOS DE MEDIANO Y PEQUEÑO TAMAÑO, ESPECIALMENTE VASOPRESINA, OXITOCINA Y SUS ANALOGOS, QUE CONSTA DE DICHO PEPTIDO, UNA CUBIERTA ENTERICA Y UN VEHICULO ACEPTABLE FARMACEUTICAMENTE QUE CONTIENE UN AGENTE AMORTIGUADOR A UN PH DE 2 A 6, SIENDO PREFERIBLE UN PH DE 5 APROXIMADAMENTE. EL METODO DE FABRICACION DE DOSIS SIMPLES DE DICHO PEPTIDO CONSISTE EN MEZCLAR LOS INGREDIENTES Y CONFORMAR LA MEZCLA EN ESFERAS INFERIORES A 2MM, LAS CUALES SE CUBREN CON UNA CUBIERTA ENTERICA FACILMENTE SOLUBLE EN UN JUGO GASTRICO DE PH 5.0 O MAYOR PERO NO EN UN PH SUSTANCIALMENTE INFERIOR, Y DICHAS ESFERAS CUBIERTAS SE CARGAN EN CAPSULAS O SE INTRODUCEN EN COMPRIMIDOS DEGRADABLES EN EL ESTOMAGO. TAMBIEN SE MUESTRA UN METODO PARA LA ADMINISTRACION ORAL A UN PACIENTE DE UNA DOSIS SIMPLE.
ES95914605T 1994-03-18 1995-03-09 Composicion estabilizada para la administracion oral de peptidos. Expired - Lifetime ES2149979T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9400918A SE9400918L (sv) 1994-03-18 1994-03-18 Stabiliserad komposition för oral administrering av peptider

Publications (1)

Publication Number Publication Date
ES2149979T3 true ES2149979T3 (es) 2000-11-16

Family

ID=20393330

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95914605T Expired - Lifetime ES2149979T3 (es) 1994-03-18 1995-03-09 Composicion estabilizada para la administracion oral de peptidos.

Country Status (24)

Country Link
US (1) US5763405A (es)
EP (1) EP0752877B1 (es)
JP (1) JP3249970B2 (es)
CN (1) CN1143911A (es)
AT (1) ATE194290T1 (es)
AU (1) AU679852B2 (es)
BR (1) BR9506989A (es)
CA (1) CA2183862C (es)
CZ (1) CZ285810B6 (es)
DE (1) DE69517801T2 (es)
DK (1) DK0752877T3 (es)
ES (1) ES2149979T3 (es)
FI (1) FI114688B (es)
GR (1) GR3034440T3 (es)
HU (1) HU214826B (es)
NO (1) NO316055B1 (es)
NZ (1) NZ283462A (es)
PL (1) PL181866B1 (es)
PT (1) PT752877E (es)
RO (1) RO115123B1 (es)
RU (1) RU2140790C1 (es)
SE (1) SE9400918L (es)
SK (1) SK281640B6 (es)
WO (1) WO1995025534A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922680A (en) * 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
SE9604341D0 (sv) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
EP1473029B1 (en) * 2003-04-30 2005-03-23 Ferring B.V. Solid dosage form comprising desmopressin
ATE301990T1 (de) 2003-07-25 2005-09-15 Ferring Bv Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung
EP1530967B1 (en) * 2003-11-13 2006-05-03 Ferring B.V. Blister pack and solid dosage form comprising desmopressin
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
SE528446C2 (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
AU2008283929B2 (en) 2007-08-06 2013-10-10 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
ES2319054B1 (es) 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
PL2712622T3 (pl) * 2008-05-21 2017-01-31 Ferring B.V. Ulegająca rozpadowi w ustach desmopresyna do zwiększania początkowego okresu snu niezakłócanego przez nokturię
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
ES2638815T5 (en) 2009-06-18 2025-06-26 Acerus Pharmaceuticals Usa Llc Safe desmopressin administration
EP2598553B1 (en) * 2010-07-26 2016-04-27 Université de Genève Compositions comprising polymers prepared from 2-hydroxyalkyl acids
CN102146122A (zh) * 2010-11-12 2011-08-10 深圳市健元医药科技有限公司 一种具有宫缩作用药物的生产工艺
SE536091C2 (sv) * 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
PL3200764T3 (pl) * 2014-10-01 2020-12-28 Oxytone Bioscience B.V. Rozpadająca się w jamie ustnej stała farmaceutyczna jednostka dawkowania zawierająca substancję kontrolującą poród
WO2019180561A1 (en) * 2018-03-20 2019-09-26 Mankind Pharma Ltd. Stable pharmaceutical composition of vasopressin
AU2019345313A1 (en) 2018-09-20 2021-03-18 Levo Therapeutics, Inc. Carbetocin drug product and process for preparing same
KR20210062638A (ko) 2018-09-20 2021-05-31 레보 테라퓨틱스 인코포레이티드 카르베토신의 안정한 비강내 제형

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH495957A (de) * 1966-09-15 1970-09-15 Ceskoslovenska Akademie Ved Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids
US4271068A (en) * 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
CH517705A (de) * 1969-12-16 1972-01-15 Ciba Geigy Ag Verfahren zur Herstellung von Cystin-haltigen Peptiden
US3929758A (en) * 1974-09-12 1975-12-30 Armour Pharma Cyclization of cysteine-containing peptides
US4033940A (en) * 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4093610A (en) * 1977-01-31 1978-06-06 American Home Products Corporation Process for producing triglycyl-lysine vasopressin and intermediates therefor
US4216141A (en) * 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
DE2923787A1 (de) * 1979-06-12 1980-12-18 Max Planck Gesellschaft Verfahren zur selektiven bildung von disulfidbruecken in polypeptiden und die dabei erhaltenen produkte als wirkstoffe enthaltende arzneimittel
IE56021B1 (en) * 1982-10-13 1991-03-27 Akzo Nv Peptides
SE8306367L (sv) * 1983-11-18 1985-05-19 Ferring Ab Antidiuretiskt verkande farmaceutiskt preparat
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
US5066716A (en) * 1988-12-13 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthesis of chloroacetyl and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides
SE9300937L (sv) * 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
CN1101701C (zh) * 1993-06-29 2003-02-19 凡林有限公司 由鼻给药的去氨加压素组合物及其制备方法和用途
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5500413A (en) * 1993-06-29 1996-03-19 Ferring Ab Process for manufacture of 1-deamino-8-D-arginine vasopressin

Also Published As

Publication number Publication date
DE69517801T2 (de) 2001-02-22
NO316055B1 (no) 2003-12-08
NO963884L (no) 1996-09-17
DK0752877T3 (da) 2000-10-16
AU2151795A (en) 1995-10-09
SE9400918D0 (sv) 1994-03-18
US5763405A (en) 1998-06-09
DE69517801D1 (de) 2000-08-10
SK281640B6 (sk) 2001-06-11
NZ283462A (en) 1997-03-24
EP0752877B1 (en) 2000-07-05
HU9602544D0 (en) 1996-11-28
CN1143911A (zh) 1997-02-26
CZ285810B6 (cs) 1999-11-17
SE9400918L (sv) 1995-09-19
HU214826B (hu) 1998-06-29
PL181866B1 (pl) 2001-09-28
EP0752877A1 (en) 1997-01-15
FI963679A0 (fi) 1996-09-17
FI114688B (fi) 2004-12-15
SK118596A3 (en) 1997-04-09
JP3249970B2 (ja) 2002-01-28
RO115123B1 (ro) 1999-11-30
PT752877E (pt) 2000-12-29
NO963884D0 (no) 1996-09-17
WO1995025534A1 (en) 1995-09-28
CZ267696A3 (en) 1997-05-14
JPH10503467A (ja) 1998-03-31
HUT74878A (en) 1997-02-28
BR9506989A (pt) 1997-09-16
FI963679L (fi) 1996-09-17
GR3034440T3 (en) 2000-12-29
CA2183862C (en) 2001-10-23
CA2183862A1 (en) 1995-09-28
ATE194290T1 (de) 2000-07-15
PL316412A1 (en) 1997-01-06
RU2140790C1 (ru) 1999-11-10
AU679852B2 (en) 1997-07-10

Similar Documents

Publication Publication Date Title
ES2149979T3 (es) Composicion estabilizada para la administracion oral de peptidos.
ES2126536A1 (es) "preparado farmaceutico para administracion intranasal"y procedimiento para su produccion.
ES2157975T3 (es) Soluciones farmaceuticas con solubilidad mejorada.
EP0121321A3 (en) Pharmaceutical compositions
CA2112679A1 (en) Dosage form for delivering drug in short-time period
IL136285A0 (en) Pharmaceutical compositions containing an acid-labile active component
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
CA2168732A1 (en) Gelatin Capsules Containing a Highly Concentrated Acetaminophen Solution
ES2161690T3 (es) Formulaciones farmaceuticas.
IL142801A0 (en) Pharmaceutical compositions containing an adenosine analog
IL88460A0 (en) Stabilized medicinal substances,a process for the preparation thereof,and stable medicinal formulations
AU547175B2 (en) Stabilised prostaglandin formulations
NZ225242A (en) Pad printing process for manufacturing a pharmaceutical presentation and/or dosage form for active ingredients of drugs
AR011919A1 (es) FORMULACIoN EN COMPRIMIDOS O CÁPSULAS PARA TRAGAR DE PARACETAMOL (N-ACETIL-P-AMINOFENOL) Y PROCEDIMIENTO PARA PREPARARLA
ES2135570T3 (es) Composicion para la administracion oral de peptidos.
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
ATE227304T1 (de) Tetraetherlipide und diese enthaltende liposomen sowie deren verwendung
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
DE3263832D1 (en) Gallium chloride, an anti-cancer drug
AR003434A1 (es) Compuesto de tiludronato, composiciones farmaceuticas que los contienen y proceso para producir dicho compuesto y procedimiento para producir lascomposiciones farmaceuticas.
MY100780A (en) Azumolene dosage form.
DE3266072D1 (en) Method for the oral administration of substances in the form of liposomes, and relative pharmaceutical compositions
JPS577422A (en) Crocosmia aurea "plach"
ES2127305T3 (es) Una forma farmaceutica para la administracion rectal de compuestos farmacologicamente activos.
GB1110397A (en) Ephedrine composition

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 752877

Country of ref document: ES